Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Angela Russell, Professor of Medicinal Chemistry in the Oxford Departments of Pharmacology and Chemistry, has been announced as one of the five recipients of the inaugural UK Rare Disease Scholar Award, presented by the Harrington Discovery Institute (HDI).

Professor Angela RussellThrough its UK charity, Fund for Cures UK, with Morgan Stanley GIFT Cures, HDI issued a call for proposals for cutting-edge research in rare diseases and rare variants of more common diseases. Around 350 million people worldwide have a rare disease, half of which are children. Of the 7,000 known rare diseases, only five percent have an approved treatment. Rare diseases represent one of the greatest unmet needs in global healthcare today.

In addition to her joint appointment between Pharmacology and Chemistry, Professor Russell is a member of the MDUK Oxford Neuromuscular Centre. She aims to develop new drugs for the treatment of Duchenne Muscular Dystrophy, a severe muscle disease with childhood onset.

Speaking of the launch of the Rare Disease Scholar Awards in the UK, Jonathan Stamler, President of the HDI, said, “In eight years we have built a strong portfolio of breakthrough science throughout the US and Canada, and we are excited to extend our reach to the United Kingdom. Together with our Scholars and their institutions, we are pleased to move one step closer to changing the rare disease landscape in a meaningful way.”

In response to the announcement of her award, Professor Russell commented, “I’m delighted to have been awarded a 2021 Harrington UK Rare Diseases Scholarship. The support and guidance the Harrington team provide will be instrumental to allow us to build on our collaborative work with Professor Dame Kay Davies’ group (DPAG), to develop a small molecule drug to increase utrophin levels at the muscle membrane to treat Duchenne muscular dystrophy patients.”

Similar stories

Professor Fran Platt elected to The Royal Society

We were delighted to learn from the announcement today, 6 May 2021, that Professor Fran Platt has been elected a Fellow of The Royal Society. She is one of the 52 distinguished scientists whose election was announced, and one of the two biologists out of six Oxford academics so-honoured this year. https://royalsociety.org/news/2021/05/new-fellows-announcement-2021/

Success for Dr Kerstin Timm with AMS Springboard grant

Dr Kerstin Timm in the Department of Pharmacology has been announced as one of the latest round of PIs to secure an AMS Springboard Award. The AMS Springboard award is highly competitive and is intended for new independent researchers in biomedical sciences, who have been in their role for less than 4 years and have not received more than £150,000 in grant money. The Springboard award thus allows new PIs to launch a new independent program of research, and awards are made for up to £100,000 over 2 years.

John Parrington launches ‘Mind Shift: How culture transformed the human brain’

A new book is published this week by Oxford University Press written by Associate Professor John Parrington. ‘Mind Shift’ draws on new scientific evidence to offer a substantive material explanation of self-conscious awareness in humans.

Vasudevan lab identifies novel means of improving sensitivity and efficiency for PCR COVID testing

In collaboration with the infectious disease units at the John Radcliffe and Churchill Hospitals, the Vasudevan lab has identified a novel means of improving RT-qPCR sensitivity and efficiency for the detection of SARS-CoV-2 through the concentration of pooled patient lysates.